Stockscreener 앱 받기
35.91
1.07%
0.38
전일 마감가:
$35.53
열려 있는:
$35.54
하루 거래량:
284.13K
Relative Volume:
0.66
시가총액:
$1.74B
수익:
$441.33M
순이익/손실:
$9.76M
주가수익비율:
179.73
EPS:
0.1998
순현금흐름:
$839.00K
1주 성능:
-1.16%
1개월 성능:
+5.09%
6개월 성능:
-22.79%
1년 성능:
+51.07%
1일 변동 폭
$34.70
$36.13
1주일 범위
$34.24
$36.79
52주 변동 폭
$24.53
$48.25
Artivion Inc Stock (AORT) Company Profile
명칭
Artivion Inc
전화
(770) 419-3355
주소
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
35.91 | 1.74B | 441.33M | 9.76M | 839.00K | 0.1998 |
ABT
Abbott Laboratories
|
87.17 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2025-08-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2025-06-17 | 개시 | Canaccord Genuity | Buy |
| 2024-10-23 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-27 | 재확인 | Lake Street | Buy |
| 2022-08-08 | 개시 | Lake Street | Buy |
| 2022-03-03 | 개시 | Stifel | Buy |
모두보기
Artivion Inc 주식(AORT)의 최신 뉴스
Artivion Q1 2026 Earnings Preview — May 7, Street Expects $0.12 EPS - AlphaStreet
Earnings Preview: Artivion to Report Financial Results Post-market on May 07 - Moomoo
Freedom Capital Markets initiates Artivion stock with buy rating By Investing.com - Investing.com Australia
Freedom Capital Markets initiates Artivion stock with buy rating - Investing.com
Ladenburg Thalmann upgrades Artivion (AORT) - MSN
Artivion, Inc. (NYSE:AORT) Sees Large Growth in Short Interest - MarketBeat
Artivion (AORT) to Release Quarterly Earnings on Thursday - MarketBeat
Artivion (AORT) soars 5.3%: Is further upside left in the stock? - MSN
Conestoga Capital Adds Artivion to Portfolio Amid Market Volatility - HarianBasis.co
Strong Catalysts Drive Artivion (AORT) - Insider Monkey
What are the risks of Artivion (AORT) stock today | Artivion Logs 40% EPS Miss Below Analyst EstimatesMoat - Newser
Artivion (NYSE:AORT) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Artivion's next earnings update lands May 7, with a 4:30 p.m. ET webcast - Stock Titan
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results - marketscreener.com
AORT (Artivion Inc.) shares fall 1.26% after Q4 2025 EPS lands 40% below consensus analyst estimates.Social Investment Platform - Cổng thông tin điện tử tỉnh Lào Cai
AORT (Artivion) shares climb 2.86 percent on the day despite a 40 percent Q4 2025 EPS miss versus analyst estimates.Retail Trader Ideas - Xã Thanh Hà
Price Action Overview | Artivion posts 40% EPS miss below Street estimatesPerformance Review - UBND thành phố Hải Phòng
Artivion (AORT) Stock: Price Action Overview | Artivion posts 40% EPS miss below Street estimatesPerformance Review - Cổng thông tin điện tử tỉnh Lào Cai
Artivion, Inc. (NYSE:AORT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Will FDA Approval Of NEXUS And Endospan Option Reshape Artivion's (AORT) Minimally Invasive Aortic Strategy - simplywall.st
Artivion (AORT) Gains Conviction List Spot with Strong Buy Ratin - GuruFocus
Artivion, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
Artivion shows improved relative strength; still shy of benchmark - MSN
How The Investment Story Is Shifting For Artivion (AORT) After Recent Analyst And FDA Updates - Yahoo Finance
Artivion (AORT) Stock: Why It Matters This Year (-1.95%) 2026-04-16Crowd Risk Alerts - UBND thành phố Hải Phòng
Assessing Artivion (AORT) Valuation After FDA Approval Of NEXUS Aortic Arch System - simplywall.st
Tudor Investment Corp ET AL Sells 39,388 Shares of Artivion, Inc. $AORT - MarketBeat
Artivion (NYSE:AORT) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 85 Tel - GuruFocus
LADENBURG THALM/SH SH Upgrades Artivion (NYSE:AORT) to Buy - MarketBeat
Endospan’s FDA nod for Nexus brings acquisition by Artivion closer - BioWorld News
Growth Value: Is Artivion Inc a momentum stock2026 Growth vs Value & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Artivion secures FDA approval for NEXUS aortic arch system - MSN
Artivion Receives FDA Clearance for NEXUS Aortic Arch System - Bitget
Artivion Secures FDA Approval for NEXUS Aortic Arch System - Zacks Investment Research
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
UnitedHealth, Alignment Healthcare, Humana And Other Big Stocks Moving Higher On Tuesday - Sahm
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Artivion, Inc. (AORT) Stock forecasts - Yahoo Finance UK
Artivion (AORT) Receives "Buy" Rating Reiteration from Needham | - GuruFocus
FDA Greenlights Artivion's (AORT) Nexus Aortic Arch System - GuruFocus
Artivion Inc (AORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.93%
자본화:
|
볼륨(24시간):